FDA Approves Co-Packaging of Ribociclib With Letrozole for Metastatic Breast Cancer

May 9, 2017 – The FDA has approved co-packaging of the oral medications ribociclib and letrozole for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer. With the new Ribociclib Letrozole Co-Pack, patients can obtain a full 28-day cycle of the 2 medicines in 1 package with 1 prescription and 1 copay, and the cost will be the same as that for Kisqali alone, according to Novartis, which manufactures both medications. “Providing … (leggi tutto)